Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics is well positioned fundamentally because its lead PRMT5 inhibitor vopimetostat has shown differentiated safety and efficacy, including 92% ORR and 90% 6-month PFS in 2L/3L PDAC, which strengthens its case as a backbone combination therapy in MTAP-deleted cancers. The company’s ~$1B cash balance at 2Q26 supports a substantial runway for ongoing clinical and preclinical programs, including the planned Phase 3 design in 1H26 and multiple 2H26 catalysts such as ESMO 2026 data and initial TNG456 results in GBM. With roughly 10,000 annual US treatment-eligible PDAC patients and 2,700-4,000 in NSCLC, Tango’s late-stage transition and strategic optionality across PRMT5/KRAS combinations underpin a favorable long-term outlook.

Tango Therapeutics is viewed negatively because its value depends heavily on unproven clinical success for TNG462 and TNG456, while the company still faces meaningful execution risk in advancing registrational plans and obtaining timely regulatory approvals. The bullish case relies on a DCF using a 10% discount rate, 1.5% terminal growth, and approval probabilities of 50% in 1L+ NSCLC and 65% in 2L+ PDAC, yet the model still highlights downside if combination efficacy, physician uptake, or therapy duration assumptions prove too optimistic. With significant capital needs and stated long-term dilution risk, plus intense competition from other PRMT5 inhibitors and KRAS therapies, the fundamentals look fragile despite the $11.6B implied market value.